{"entity":{"id":"nct03767348","kind":"trial","name":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)","aka":[],"tldr":"A phase 2 trial of Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Replimune, Inc., active and no longer recruiting.","summary":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) is a phase 2 interventional study registered as NCT03767348 by Replimune, Inc., with 340 participants planned, started 2017-09-20 and due to reach its primary completion in 2028-06. Interventions recorded: RP1, nivolumab. Conditions listed: Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03767348","url":"https://clinicaltrials.gov/study/NCT03767348"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","melanoma","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":["replimune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03767348","phase":"2","setting":"An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]","sponsor":"Replimune, Inc.","enrolled":340,"outcomes":[]},"route":"/trials/nct03767348/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"replimune","kind":"company","name":"Replimune","route":"/companies/replimune/"}]}}